

# Theodora Hatziioannou

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6170729/publications.pdf>

Version: 2024-02-01

48  
papers

13,939  
citations

136740

32  
h-index

205818

48  
g-index

79  
all docs

79  
docs citations

79  
times ranked

19819  
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasma Neutralization of the SARS-CoV-2 Omicron Variant. <i>New England Journal of Medicine</i> , 2022, 386, 599-601.	13.9	371
2	Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins. <i>Immunity</i> , 2022, 55, 998-1012.e8.	6.6	86
3	Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost. <i>Nature</i> , 2022, 607, 128-134.	13.7	197
4	Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization After Messenger RNA Vaccination and Variant Breakthrough Infection. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	5
5	Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: a serological analysis. <i>Lancet Microbe</i> , The, 2022, 3, e493-e502.	3.4	22
6	Antibody and Memory B-Cell Immunity in a Heterogeneously SARS-CoV-2-Infected and -Vaccinated Population. <i>MBio</i> , 2022, 13, .	1.8	9
7	Antibody evolution to SARS-CoV-2 after single-dose Ad26.COVS vaccine in humans. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	10
8	Plasma and memory antibody responses to Gamma SARS-CoV-2 provide limited cross-protection to other variants. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	6
9	Absence of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Activity in Prepandemic Sera From Individuals With Recent Seasonal Coronavirus Infection. <i>Clinical Infectious Diseases</i> , 2021, 73, e1208-e1211.	2.9	65
10	Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients. <i>Journal of Infectious Diseases</i> , 2021, 223, 389-398.	1.9	233
11	Enhanced SARS-CoV-2 neutralization by dimeric IgA. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	379
12	Evolution of antibody immunity to SARS-CoV-2. <i>Nature</i> , 2021, 591, 639-644.	13.7	1,355
13	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. <i>Nature</i> , 2021, 592, 616-622.	13.7	1,232
14	Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice. <i>Nature</i> , 2021, 593, 424-428.	13.7	108
15	Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. <i>Nature</i> , 2021, 595, 426-431.	13.7	610
16	Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants. <i>Nature</i> , 2021, 595, 278-282.	13.7	154
17	Vaccine Breakthrough Infections with SARS-CoV-2 Variants. <i>New England Journal of Medicine</i> , 2021, 384, 2212-2218.	13.9	647
18	Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques. <i>PLoS Pathogens</i> , 2021, 17, e1009688.	2.1	16

#	ARTICLE	IF	CITATIONS
19	Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. <i>Nature Communications</i> , 2021, 12, 4196.	5.8	332
20	Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. <i>Immunity</i> , 2021, 54, 1853-1868.e7.	6.6	230
21	Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies. <i>Cell Reports</i> , 2021, 36, 109760.	2.9	80
22	Comparison of SARS-CoV-2 serological assays for use in epidemiological surveillance in Scotland. <i>Journal of Clinical Virology Plus</i> , 2021, 1, 100028.	0.4	2
23	High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. <i>Nature</i> , 2021, 600, 512-516.	13.7	174
24	Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency. <i>Cell Reports Medicine</i> , 2021, 2, 100164.	3.3	26
25	Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	283
26	Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. <i>Nature</i> , 2021, 600, 517-522.	13.7	239
27	Replication and single-cycle delivery of SARS-CoV-2 replicons. <i>Science</i> , 2021, 374, 1099-1106.	6.0	49
28	Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations. <i>Nature Immunology</i> , 2021, 22, 1503-1514.	7.0	40
29	Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape. <i>ELife</i> , 2021, 10, .	2.8	36
30	Convergent antibody responses to SARS-CoV-2 in convalescent individuals. <i>Nature</i> , 2020, 584, 437-442.	13.7	1,742
31	Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	503
32	Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. <i>Cell</i> , 2020, 182, 828-842.e16.	13.5	724
33	Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. <i>ELife</i> , 2020, 9, .	2.8	1,239
34	Flexibility in Nucleic Acid Binding Is Central to APOBEC3H Antiviral Activity. <i>Journal of Virology</i> , 2019, 93, .	1.5	8
35	Derivation of simian tropic HIV-1 infectious clone reveals virus adaptation to a new host. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 10504-10509.	3.3	14
36	Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes. <i>PLoS Pathogens</i> , 2019, 15, e1007632.	2.1	20

#	ARTICLE	IF	CITATIONS
37	Rhabdo-immunodeficiency virus, a murine model of acute HIV-1 infection. <i>ELife</i> , 2019, 8, .	2.8	6
38	A single gp120 residue can affect HIV-1 tropism in macaques. <i>PLoS Pathogens</i> , 2017, 13, e1006572.	2.1	28
39	Envelope residue 375 substitutions in simianâ€“human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E3413-22.	3.3	170
40	Selection of Unadapted, Pathogenic SHIVs Encoding Newly Transmitted HIV-1 Envelope Proteins. <i>Cell Host and Microbe</i> , 2014, 16, 412-418.	5.1	47
41	HIV-1â€“induced AIDS in monkeys. <i>Science</i> , 2014, 344, 1401-1405.	6.0	76
42	MX2 is an interferon-induced inhibitor of HIV-1 infection. <i>Nature</i> , 2013, 502, 563-566.	13.7	445
43	Assisted Evolution Enables HIV-1 to Overcome a High TRIM5Î±-Imposed Genetic Barrier to Rhesus Macaque Tropism. <i>PLoS Pathogens</i> , 2013, 9, e1003667.	2.1	32
44	Animal models for HIV/AIDS research. <i>Nature Reviews Microbiology</i> , 2012, 10, 852-867.	13.6	274
45	A macaque model of HIV-1 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 4425-4429.	3.3	150
46	Tetherin-Driven Adaptation of Vpu and Nef Function and the Evolution of Pandemic and Nonpandemic HIV-1 Strains. <i>Cell Host and Microbe</i> , 2009, 6, 409-421.	5.1	391
47	Independent genesis of chimeric TRIM5-cyclophilin proteins in two primate species. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 3563-3568.	3.3	183
48	Generation of Simian-Tropic HIV-1 by Restriction Factor Evasion. <i>Science</i> , 2006, 314, 95-95.	6.0	140